These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847 [TBL] [Abstract][Full Text] [Related]
66. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol]. Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882 [TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361 [TBL] [Abstract][Full Text] [Related]
68. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. Kojima S; Matsui K; Ogawa H; Jinnouchi H; Hiramitsu S; Hayashi T; Yokota N; Kawai N; Tokutake E; Uchiyama K; Sugawara M; Kakuda H; Wakasa Y; Mori H; Hisatome I; Waki M; Ohya Y; Kimura K; Saito Y; J Cardiol; 2017 Jan; 69(1):169-175. PubMed ID: 27005768 [TBL] [Abstract][Full Text] [Related]
69. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Wortmann RL; Macdonald PA; Hunt B; Jackson RL Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107 [TBL] [Abstract][Full Text] [Related]
70. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. Bove M; Cicero AFG; Borghi C Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435 [TBL] [Abstract][Full Text] [Related]
71. Efficacy and Safety of Febuxostat in Kidney Transplant Patients. Baek CH; Kim H; Yang WS; Han DJ; Park SK Exp Clin Transplant; 2018 Aug; 16(4):401-406. PubMed ID: 29251581 [TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetics of febuxostat in healthy Chinese volunteers. Liu XX; Liu RJ; Ding L; Lin YF; Huang NY; Xiao HF; Huang Y; Yang J; Wang SL Arzneimittelforschung; 2012 Oct; 62(10):463-9. PubMed ID: 22956350 [TBL] [Abstract][Full Text] [Related]
73. Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia. Nishizawa T; Taniura T; Nomura S Blood Coagul Fibrinolysis; 2015 Dec; 26(8):887-92. PubMed ID: 26164850 [TBL] [Abstract][Full Text] [Related]
74. Febuxostat : a viewpoint by Naomi Schlesinger. Schlesinger N Drugs; 2008; 68(13):1875-6. PubMed ID: 18729539 [No Abstract] [Full Text] [Related]
75. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969 [TBL] [Abstract][Full Text] [Related]
76. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Dalbeth N; Stamp L Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242 [TBL] [Abstract][Full Text] [Related]
77. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y; Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485 [TBL] [Abstract][Full Text] [Related]
78. Renal function in gout: long-term treatment effects of febuxostat. Whelton A; Macdonald PA; Zhao L; Hunt B; Gunawardhana L J Clin Rheumatol; 2011 Jan; 17(1):7-13. PubMed ID: 21169856 [TBL] [Abstract][Full Text] [Related]
79. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia. Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065 [TBL] [Abstract][Full Text] [Related]
80. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study. Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]